Navigation Links
NHS Northamptonshire Chief Executive John Parkes Accepts Visiting Professorship
Date:9/13/2011

LONDON, September 13, 2011 /PRNewswire/ --

NHS Northamptonshire's Chief Executive, John Parkes, will be giving lectures and advising on NHS related research projects, after being offered a Visiting Professorship at The University of Northampton.

Professor Parkes commented: "I am delighted to have been offered the role and I look forward to working more closely with the staff and students there.

"NHS Northamptonshire already has excellent links with the University through the School of Health and the Centre for Health and Wellbeing Research and this latest step will further enhance our close working relationship."

Professor John Parkes is Chief Executive and Accountable Officer for the Milton Keynes and Northamptonshire PCT Cluster. Prior to his current role as a commissioner, John spent the majority of his career running provider organisations including 15 years within university hospitals.   John is a member of the national Independent Reconfiguration Panel which provides advice to the Secretary of State on disputed or controversial service reconfigurations.

This new position came about following recommendations from the Dean of the School of Health, Dr Sue Allen.  John Parkes is taking up the role of Visiting Professor in Healthcare Management at The University of Northampton. The Professorship will last for a minimum of two years.

Professor John Parkes will also input directly into the activities of the Centre for Health and Wellbeing Research, keep academic staff informed on healthcare management practices and advise the School of Health executive on current issues in the NHS.

On joining NHS Northamptonshire in October 2006 John worked together with colleagues and partners to successfully turn around the PCT's inherited deficit. John's work over the last four years has been key in NHS Northamptonshire being ranked as one of the most effective PCTs in the East Midlands as well as becoming a top performing national PCT.

In his previous role as Chief Executive of Mid Yorkshire Hospitals, John's was instrumental to moving the Trust from the worst in the country to an organisation that was fit for purpose with safe and sustainable services that could deliver national and local expectations.

Dr Sue Allen, Dean, School of Health, The University of Northampton, commented

"The appointment of John Parkes as a Visiting Professor cements and recognises the importance of individuals who are able to provide leadership based on strong research based evidence for the future of excellent healthcare and education in Northamptonshire. We look forward to working closely with John in his new role."

Notes to Editors:

The University of Northampton is dedicated to high quality higher education at undergraduate and postgraduate levels, through taught courses and research. As Northamptonshire's only dedicated higher education institution, it is committed to the transfer of knowledge and technology to the community and aims to contribute to the cultural development of the region.

The University of Northampton's RSS feed is available at http://www.northampton.ac.uk/news/feed/rss.xml

More on this story http://www.northampton.ac.uk/news/article/113/nhs-northamptonshire-chief-executive-john-parkes-accepts-visiting-professorship/200238


'/>"/>
SOURCE NHS Northamptonshire
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. John Sperzel Appointed as Chief Executive Officer of ITC Nexus Dx
2. OXIS International Names David Saloff as Chief Executive Officer
3. 3-V Biosciences Appoints George W. Kemble, PhD, as Chief Scientific Officer
4. Creabilis Appoints Dr David Roblin as Chief Medical Officer
5. Nycomed US Inc. Names Brian A. Markison as Chief Executive Officer
6. Genesis Biopharma Names Former Member of the Joint Chiefs of Staff General Merrill McPeak to Board of Directors
7. Dr. Andrew Scharenberg, M.D., to Serve as Chief Scientific Officer for Cellectis therapeutics
8. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
9. PharmacoFore, Inc. Announces Appointment of Chief Medical Officer and Vice President of Intellectual Property
10. Crescendo Biologics Appoints Matthew Roe as Chief Business Officer
11. Synthetic Genomics Inc. Appoints Joseph Mahler as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2020)... ... February 11, 2020 , ... ... services in North America, today announced that the City of Fort Worth has ... biosolids management needs. Commencing in April of 2020, Synagro will assume operation of ...
(Date:2/3/2020)... ... February 03, 2020 , ... ... MA, announce that OmniType, the 11-locus, single tube multiplex successor to Holotype HLA ... best-in-class product featuring locus-multiplexing and short library preparation, for HLA genotyping from sample ...
(Date:1/27/2020)... , ... January 27, 2020 , ... ... it has secured financing from strategic investors led by Halma plc , ... existing investors Sonion, TDF Ventures, GII LLC, and WSJ Joshua Fund. A representative ...
(Date:1/22/2020)... ... January 20, 2020 , ... Brilliant, maker of the ... largest independent electronics distributor in the US, to make it easy for homebuilders, ... leading smart home products from a single fulfillment partner. Ranging from entry-level systems ...
Breaking Biology Technology:
(Date:1/27/2020)... ... January 27, 2020 , ... Cytonus Therapeutics Inc. today announced ... entrepreneur, and former senior management consultant at McKinsey & Company who holds three ... investment firm. , “Chris Thorne has exceptional business acumen with a proven ...
(Date:1/23/2020)... ... January 23, 2020 , ... GIOSTAR/HEAMGEN has ... stem cells. The red blood cells are made utilizing a bioreactor that ... transfusion therapy and replaces the need for a human blood donor. ...
(Date:1/10/2020)... , ... January 09, 2020 , ... ... bioactive spinal solutions, today announced the 510(K) clearance and commercial launch of the ... interbody fusion system. , The EVOL®ha-DLIF is made of PEEK-OPTIMA HA Enhanced ...
Breaking Biology News(10 mins):